Biotechnology
Commented by Nico Popp on June 18th, 2026 | 07:35 CEST
The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma
There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.
Read
Commented by Matthias Schomber on June 16th, 2026 | 07:20 CEST
Vonovia is Struggling, Evotec is Reinventing Itself, and dynaCERT is Expanding—Three Stocks Under the Microscope! Who has the Upper Hand?
Three stocks, three completely different stories, yet all three are currently at a point that is likely to determine their performance over the coming months. Vonovia, for example, is struggling with rising interest rates and a real estate market that refuses to recover. Evotec is in the midst of a profound restructuring and has just reshuffled its supervisory board. And dynaCERT, the Canadian cleantech specialist, is pushing ahead in Southeast Asia: Vietnam could be the next step. On top of that, a geopolitical shock is shaking up markets: the US and Iran have reportedly reached a deal, and the Strait of Hormuz is set to reopen. Oil prices have fallen sharply in response. What this means for energy costs, real estate markets, and cleantech companies is still unclear. But a closer look reveals that all three stocks offer more than just headlines. Where should investors enter now?
Read
Commented by Stefan Feulner on June 15th, 2026 | 07:40 CEST
Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination
The biotech sector is currently experiencing tremendous momentum. Therapies for obesity, diabetes, autoimmune diseases, and neurological conditions, in particular, rank among the largest growth markets in the healthcare industry. The booming GLP-1 market for weight loss and metabolic disorders alone is expected to reach a volume of tens of billions of USD in the coming years. At the same time, new classes of active ingredients and innovative delivery technologies are providing fresh momentum. Investors find themselves in an environment where clinical advances and technological innovations can trigger significant increases in value.
Read
Commented by Armin Schulz on June 12th, 2026 | 06:40 CEST
The Biotech and Life Sciences Boom: Evotec, BioNxt Solutions, and Merck – Which Is Worth Investing In?
The life sciences and pharmaceutical industry is undergoing a structural transformation. Value creation is no longer driven by individual blockbuster drugs, but rather by platform technologies, patent portfolios, and strategic deals. This new capital market logic rewards companies with protectable intellectual property and smart licensing agreements—not just pure pipeline developers. For private investors, this creates high-yield niches with reduced regulatory risks. The key question remains: who controls the levers in the innovation ecosystem? Those who recognize this structure early can benefit disproportionately. Today we focus on Evotec, BioNxt Solutions, and Merck.
Read
Commented by Tarik Dede on June 11th, 2026 | 07:05 CEST
Wave of Biotech Acquisitions: Eli Lilly, Vidac Pharma, and GSK in the Spotlight
Cancer remains one of humanity's greatest scourges, and at the same time, it is by far the largest healthcare market of all. But the old-school pharmaceutical giants are running out of oncology pipeline candidates, and now smaller, far more innovative players are increasingly being acquired. The M&A market is currently experiencing extremely dynamic times. This week, for example, GSK announced the acquisition of Nuvalent for USD 10.6 billion in cash. Gilead Sciences, in turn, struck a deal in April with the German company Tubulis—for a total of USD 5 billion. Shortly thereafter, Eli Lilly offered up to USD 7 billion for Kelonia Therapeutics, just to name a few of this year's deals. That is why we are taking a look at the opportunities in the sector today and putting the stocks of Eli Lilly, Vidac Pharma, and GSK under the microscope!
Read
Commented by Armin Schulz on June 11th, 2026 | 06:45 CEST
With Novo Nordisk, MustGrow Biologics, and Bayer: Positioning for Two Megatrends of the Decade
Created and published on behalf of MustGrow Biologics Corp.
Two seemingly opposing crises—obesity and food scarcity—are creating major investment opportunities this year. While the obesity epidemic is placing increasing strain on healthcare systems, climate shocks and geopolitical conflicts are threatening global agricultural yields. The biotech sector is addressing both challenges through biological compounds for weight management and crop protection. Demand for effective obesity treatments and sustainable agricultural solutions is rising rapidly. Investors who position themselves early in the beneficiaries of this dual transformation may benefit from above-average returns. This is precisely where the three companies we are taking a closer look at today are positioned: Novo Nordisk, MustGrow Biologics, and Bayer.
Read
Commented by Carsten Mainitz on June 4th, 2026 | 07:45 CEST
Takeover Fever! BioNxt Solutions, Delivery Hero, and Commerzbank in the Spotlight: How Investors Can Benefit!
The entry of a strategic investor or the prospect of a takeover regularly leads to significant price surges and even massive revaluations. The momentum is enormous; the global market for mergers and acquisitions has reached new records. Especially during periods of technological upheaval, geopolitical realignment, and increasing competitive pressure, companies are increasingly turning to acquisitions to secure growth, resources, or market share. In this context, there are exciting and lucrative developments for investors at BioNxt Solutions, Delivery Hero, and Commerzbank. The investment case for BioNxt Solutions is particularly compelling. The Canadian company aims to bring an alternative to weight-loss injections to market. If successful, this could create a billion-dollar business and attract acquirers. How should investors position themselves?
Read
Commented by Armin Schulz on June 3rd, 2026 | 07:25 CEST
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer
An aging population is driving rapid increases in healthcare spending. A trillion-dollar market is emerging in the cancer sector, as over 30 million new cases are expected annually by 2040. As traditional chemotherapy approaches its limits, new technologies and ideas are needed. Those who set the course today can benefit from this transformation, even if not every approach will succeed. The key question remains: which companies possess the key technologies to benefit from this boom? Three players are coming into particular focus: BioNTech with its mRNA platform, Vidac Pharma with a patented metabolic approach, and Pfizer with its multi-billion-dollar acquisitions.
Read
Commented by Fabian Lorenz on May 29th, 2026 | 09:40 CEST
A 4,000% gain is not enough? SanDisk, BioNTech, and Standard Uranium
60% in one month, 600% in six months, and 4,000% in one year. Yet there is still no sign of a major correction in SanDisk's stock. Even now, analysts are still raising their price targets significantly and joining the bulls' camp. In contrast, the uranium sector is currently on the sidelines. This offers a chance for contrarian investors. After all, it can really only be a matter of time before the industry is rediscovered as an AI winner. One exciting stock is Standard Uranium. The CEO recently made a strong impression at an investor conference. And what about BioNTech? Investors are disappointed, but analysts are positive. Can the biotech company provide new momentum starting today with new data from its oncology pipeline?
Read
Commented by Fabian Lorenz on May 26th, 2026 | 07:30 CEST
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock?
Investor sentiment around Novo Nordisk is improving. Shares of the Danish pharmaceutical giant appear to be breaking out of the downtrend that began in the summer of 2024, with investors responding positively to recent developments. At Vidac Pharma, the latest announcement seems to have gone largely unnoticed. Yet it could mark the beginning of interest from strategic investors. There is even speculation about a potential full takeover of the oncology specialist. With a market capitalization of only around EUR 33 million, any acquisition would likely require a substantial premium. While investors may be knocking on Vidac's door, sentiment toward BioNTech has deteriorated. The company's founding couple is stepping down, and locations are being closed. And now analysts are also questioning the quality of the company's product pipeline.
Read